You are viewing: India Cell Therapy Technologies Market analysis

The India Cell Therapy Technologies Market was valued at $66.8 Million in 2025 and projected to reach to $131.7 Million by 2030, representing a compound annual growth rate of 14.6%. India's cell therapy technologies market is poised for exceptional growth, driven by a convergence of favorable factors including rising healthcare expenditure, expanding middle-class population seeking advanced treatments, and improving regulatory pathways for cell-based therapeutics.

India Cell Therapy Technologies Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Cell Therapy Technologies Market Trends and Insights

  • India's market growth rate of 14.6% CAGR significantly outpaces global trends, driven by increasing healthcare investments, rising prevalence of chronic diseases, and growing adoption of advanced therapeutic solutions.
  • India's position as a global hub for biopharmaceutical innovation and cost-effective manufacturing strengthens its competitive advantage in cell therapy development. The cell therapy landscape in India is characterized by expanding research infrastructure, government support for regenerative medicine, and rising patient awareness.
  • India's pharmaceutical and biotech sectors are increasingly investing in cell therapy platforms, including CAR-T cell therapies, stem cell treatments, and immunotherapies.
  • By 2030, India is expected to capture a larger share of the Asia Pacific cell therapy market, supported by regulatory framework improvements and strategic partnerships with international research institutions. India's demographic profile—with a large patient population and growing middle-class healthcare spending—creates substantial demand for innovative cell therapy solutions.
  • India's market trajectory reflects both domestic clinical adoption and emerging export opportunities in cell therapy manufacturing and services across the Asia Pacific region..

Key Market Statistics

  • CAGR (2025-2030) 14.6% CAGR
  • Market Size, 2025 ~USD 66.8 Million
  • Forecast, 2030 ~USD 131.7 Million
  • Country India

India Cell Therapy Technologies Market Overview

Fastest Growing Market in Asia :

India's cell therapy market is expanding at 14.6% CAGR, significantly outpacing the global growth rate of 12.4%, positioning it as one of the most dynamic markets in the Asia-Pacific region.

Substantial Market Valuation Growth :

The Indian market is projected to nearly double from USD 66.8 million in 2025 to USD 131.7 million by 2030, reflecting strong investor confidence and increasing clinical adoption across therapeutic areas.

Rising Chronic Disease Burden :

India's growing prevalence of cancer, diabetes, and cardiovascular diseases is driving demand for innovative cell therapy solutions as patients and healthcare providers seek advanced treatment alternatives.

Government Healthcare Investment Surge :

Increased government funding through initiatives like National Health Mission and Ayushman Bharat, combined with regulatory framework improvements, are accelerating cell therapy market penetration across Indian healthcare institutions.

India Cell Therapy Technologies Market Dynamics

  • The country's robust pharmaceutical and biotechnology infrastructure, coupled with cost-effective manufacturing capabilities, positions India as an emerging hub for cell therapy development and commercialization. The forecast period through 2030 will witness increased adoption of CAR-T cell therapies, stem cell treatments, and regenerative medicine solutions across major metropolitan centers and tier-2 cities.
  • Strategic partnerships between Indian biotech firms and global cell therapy leaders, combined with growing clinical trial activities and patient awareness, will further accelerate market expansion and establish India as a key player in the global cell therapy landscape..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • India's cell therapy market is valued at USD 66.8 million in 2025 and is forecast to double to USD 131.7 million by 2030, representing a 14.6% CAGR.
    • India's growth rate outpaces the global average of 12.4%, positioning India as a high-growth market within the Asia Pacific region.
    • India's expanding biotech infrastructure, government support, and cost-effective manufacturing capabilities are driving accelerated adoption of cell therapy technologies.
    • India's large patient population and rising healthcare spending create significant demand for innovative cell therapy solutions across oncology, immunology, and regenerative medicine.

    Cell Therapy Technologies Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment MEDIA, SERA, AND REAGENTS (Product)
    Forecast Period 2025–2030
    Growth Rate CAGR of 12.4% from 2025 to 2030
    Largest Segment T-CELLS (Cell Type)
    Market Size Base Year (Billions) ~USD 4.41 (2025)
    Revenue Forecast (Billions) ~USD 7.91 (2030)
    Segments Covered Product, Type, Process, Cell Type

    India Cell Therapy Technologies Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Product

    • Cell Culture Vessels
    • Cell Engineering Products
    • Cell Therapy Equipment
    • Media, Sera, And Reagents
    • Other Products
    • Systems & Software

    By Type

    • Cell Characterization
    • Cell Collection
    • Cell Expansion
    • Cell Isolation
    • Cell Processing Equipment
    • Other Cell Therapy Equipment
    • Single-Use Equipment

    By Process

    • Cell Distribution
    • Cell Handling
    • Cell Preservation
    • Cell Processing
    • Process Monitoring And Quality Control

    By Cell Type

    • Other Cells
    • Stem Cells
    • T-Cells

    INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES54.657.664.17281.693.7108.9128.715
    CELL BANKS9.29.710.411.312.313.615.217.310.6
    CROS & CMOS44.44751.657.163.872.382.996.613.4
    RESEARCH INSTITUTES15.316.117.418.920.923.326.330.111.7
    TOTAL123.6130.4143.5159.3178.7202.8233.2272.813.7

    Target Audience

    • Pharmaceutical & Biotech Companies : Multinational and domestic pharma firms seeking to expand cell therapy portfolios in India need market sizing, competitive landscape, and regulatory pathway intelligence to guide product development and commercialization strategies.
    • Healthcare Investors & Private Equity : Investment firms evaluating opportunities in Indian cell therapy startups and healthcare infrastructure require detailed market forecasts, growth drivers, and valuation benchmarks to assess investment potential and exit opportunities.
    • Hospital Networks & Healthcare Providers : Leading Indian hospital chains and diagnostic centers need market insights on cell therapy adoption trends, patient demand, reimbursement models, and clinical evidence to inform service expansion and infrastructure investments.
    • Government & Regulatory Bodies : Indian health ministry officials and regulatory agencies require market data and international best practices to develop evidence-based policies, reimbursement frameworks, and clinical trial guidelines for cell therapy technologies.
    • Contract Research & Manufacturing Organizations : CROs and CMOs operating in India need market demand forecasts and therapeutic pipeline intelligence to identify growth segments, plan manufacturing capacity, and develop specialized capabilities in cell therapy production.

    Key Companies in the India Cell Therapy Technologies Market

    CompanyHQOwnershipStrongest segments
    GENERAL ELECTRICUnited StatesPublic CompanyCommercial Engines & Services,Defense & Propulsion Technologies,Additive, Components, and Other Systems,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, instruments, bioprocessing, CDMO/testing services),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor materials, specialty gases, display and OLED materials, delivery equipment),
    SARTORIUS AGGermanyPublic CompanyBioprocess solutions (bioreactors, filtration, fluid management, process chromatography),Lab products and services (weighing, pipettes, lab filtration, water systems, microbiological testing),Advanced analytics and PAT (BLI, cytometry screening, SPR, live-cell imaging, data analytics),
    FRESENIUS SE & CO. KGAAGermanyPublic CompanyFresenius Helios (hospitals and care centers),IV generics and IV fluids,Clinical nutrition (enteral and parenteral),
    CORNING INCORPORATEDUnited StatesPublic CompanyOptical communications (fiber, cable, hardware, connectivity),Display glass substrates (LCD and OLED),Specialty materials (mobile, semiconductor optics, aerospace, defense, sunglasses, shielding),
    TERUMO CORPORATIONJapanPublic CompanyCardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company,
    BIO-TECHNEUnited StatesPublic CompanyProtein Sciences reagents and proteomic tools,Diagnostics controls, calibrators, and assays,Spatial biology and advanced genomic assays,
    GENSCRIPTHong KongPublic CompanyLife Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
    MAXCYTEUnited StatesPublic CompanyExPERT GTx and VLx (large and very large scale therapeutic applications),ExPERT STx (flow electroporation for protein production and drug development),ExPERT ATx (static electroporation for small to medium scale),

    GENERAL ELECTRIC

    General Electric is a diversified American industrial conglomerate founded in 1892 that operates across multiple sectors including power, renewable energy, aviation, and healthcare. As a public company, GE employs approximately 57,000 people globally and maintains a significant presence in industrial manufacturing and technology.

    MERCK KGAA

    Merck KGaA is a German pharmaceutical, chemical, and life sciences company founded in 1668 with approximately 59,077 employees worldwide. Operating as a public company, Merck KGaA serves customers across the healthcare, life science, and performance materials sectors.

    SARTORIUS AG

    Sartorius AG is a German life sciences and laboratory equipment company founded in 1870 with 14,242 employees. As a public company, Sartorius specializes in bioprocess solutions, laboratory instruments, and weighing technology for pharmaceutical and biotechnology industries.

    FRESENIUS SE & CO. KGAA

    Fresenius SE & Co. KGaA is a German healthcare company founded in 1912 with 177,783 employees, making it one of the largest healthcare service providers globally. Operating as a public company, Fresenius provides dialysis products and services, hospital care, and pharmaceutical products.

    CORNING INCORPORATED

    Corning Incorporated is an American materials science company founded in 1851 with 67,200 employees that specializes in glass, ceramics, and optical physics. As a public company, Corning serves industries including telecommunications, display technology, environmental solutions, and life sciences.

    TERUMO CORPORATION

    Terumo Corporation is a Japanese medical device and pharmaceutical company founded in 1921 with 30,591 employees. As a public company, Terumo develops and manufactures products for cardiovascular systems, general hospital care, transfusion and cell therapy, and vascular intervention.

    BIO-TECHNE

    Bio-Techne is an American life sciences company founded in 1976 with 3,100 employees that provides tools and reagents for research and diagnostics. Operating as a public company, Bio-Techne serves the biotechnology, pharmaceutical, and academic research sectors.

    GENSCRIPT

    GenScript is a Hong Kong-based biotechnology company founded in 2002 with 6,165 employees specializing in synthetic biology and life science research services. As a public company, GenScript provides gene synthesis, protein production, and drug discovery solutions to pharmaceutical and research organizations.

    MAXCYTE

    MaxCyte is a small American biotechnology company founded in 1998 with 91 employees focused on cell engineering and manufacturing technologies. Operating as a public company, MaxCyte develops platforms for ex vivo cell therapy production.

    Reasons to Buy this Report

    • Identify High-Growth Investment Opportunities : Gain detailed insights into India's 14.6% CAGR market dynamics to identify emerging biotech companies, manufacturing hubs, and therapeutic segments offering superior returns compared to mature global markets.
    • Strategic Market Entry Planning : Understand India-specific regulatory pathways, reimbursement landscapes, and healthcare infrastructure requirements essential for successful market entry and localization strategies for cell therapy products.
    • Competitive Intelligence for India Operations : Access comprehensive analysis of local and international competitors operating in India, their market positioning, partnerships, and clinical pipeline to inform competitive strategy and differentiation.
    • Forecast-Driven Business Development : Leverage detailed 2025-2030 projections showing market expansion from USD 66.8M to USD 131.7M to guide R&D investments, manufacturing capacity planning, and commercial resource allocation in India.
    • Risk Mitigation and Market Validation : Validate market assumptions with India-specific data on healthcare spending trends, disease prevalence, patient demographics, and adoption rates to minimize investment risks and optimize go-to-market timing.

    Frequently asked questions

    What is the current size of India's cell therapy technologies market?

    India's cell therapy technologies market is valued at USD 66.8 million in 2025, with strong growth momentum driven by healthcare investments and technological advancement.

    What is the projected market size for India's cell therapy sector by 2030?

    India's cell therapy market is forecast to reach USD 131.7 million by 2030, representing a compound annual growth rate of 14.6%.

    How does India's cell therapy market growth compare to global trends?

    India's 14.6% CAGR significantly exceeds the global average of 12.4%, making India one of the fastest-growing cell therapy markets in the Asia Pacific region.

    What factors are driving growth in India's cell therapy market?

    India's market growth is driven by expanding research infrastructure, government support for regenerative medicine, rising chronic disease prevalence, increasing healthcare spending, and India's position as a cost-effective biopharmaceutical hub.

    Which cell therapy segments are most prominent in India?

    India's cell therapy market encompasses CAR-T cell therapies, stem cell treatments, immunotherapies, and regenerative medicine applications, with growing clinical adoption across oncology and immunology sectors.

    RESEARCH METHODOLOGY

    This research study utilized extensive secondary sources, directories, and databases to identify and collect valuable information for analyzing the global cell therapy technologies market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to gather and verify critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was primarily used to identify and collect information for the comprehensive, technical, market-oriented, and commercial study of the cell therapy technologies market. The secondary sources used for this study include FDA (US Food and Drug Administration), EMA (European Medicines Agency), NIH (National Institutes of Health), ClinicalTrials.gov, PMDA (Pharmaceuticals and Medical Devices Agency, Japan), MHRA (Medicines and Healthcare products Regulatory Agency, UK), European Society of Gene and Cell Therapy (ESGCT), California Institute for Regenerative Medicine (CIRM), World Health Organization (WHO), International Society for Cell & Gene Therapy (ISCT), CBER (Center for Biologics Evaluation and Research), NIH Regenerative Medicine Program, National Medical Products Administration (NMPA), China, Health Canada – Biologics and Genetic Therapies Directorate (BGTD), Eurostat, Factiva, and GLOBOCAN, ScienceDirect; research journals; corporate filings, such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, and professional associations, among others. These sources were also utilized to gather key information about major players, market classification, and segmentation, as well as industry trends, regional/country-level markets, market developments, and technological perspectives.

    Primary Research

    After acquiring foundational knowledge about the global cell therapy technologies market through secondary research, extensive primary research was conducted. Multiple interviews were held with market experts from the demand side, including representatives from biopharmaceutical & biotechnology companies, CROs and CMOs, research institutes, and cell banks. Additionally, experts from the supply side were interviewed, including C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.

    These interviews spanned six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while the remaining 30% were with demand-side participants. The primary data was collected through various methods, including questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    Cell Therapy Technologies Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell therapy technologies market. These methods were also used extensively to estimate the size of various market segments. The research methodology used to estimate the market size includes the following:

    After determining the overall market size through the estimation process, the total market was divided into several segments and subsegments.

    Cell Therapy Technologies Market

    Data Triangulation

    After determining the market size through the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, as applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Cell therapy is a transformative area that represents a groundbreaking advancement in modern medicine, leveraging living cells to repair, replace, or regenerate damaged tissues and treat a wide range of diseases. This innovative approach involves introducing functional cells into a patient’s body to restore health, offering solutions for conditions that were once considered untreatable. With applications spanning autologous therapies, which utilize a patient’s cells, and allogeneic therapies, offering scalable off-the-shelf solutions, cell therapy is transforming healthcare delivery. The report encompasses a range of media, sera, reagents, cell engineering products, cell therapy equipment, software, and other products utilized at various stages of cell therapy, including cell collection, manufacturing, expansion, and storage.

    Stakeholders

    • Cell therapy product manufacturers, suppliers, and processors
    • Distributors and suppliers of cell therapy products
    • Biotechnology and biopharmaceutical companies
    • Contract manufacturing organizations (CMOs)
    • Suppliers and distributors of pharmaceutical products
    • Research and development (R&D) companies
    • Pharmaceutical/medical associations
    • Trade associations and industry bodies
    • Regulatory bodies and government agencies
    • Research institutes and government organizations
    • Venture capitalists and investors
    • Business research and consulting service providers
    • Market research and consulting firms

    Report Objectives

    • To define, describe, and forecast the cell therapy technologies market based on product, process, cell type, application, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall cell therapy technologies market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the global cell therapy technologies market and comprehensively analyze their product portfolios, market positions, and core competencies2
    • To track and analyze competitive developments such as product launches, acquisitions, partnerships, expansions, agreements, and collaborations in the cell therapy technologies market
    • To benchmark players within the cell therapy technologies market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and business strategy

     

    Get the Full Cell Therapy Technologies Market Report

    Full forecast, segment splits, and company analysis for all Cell Therapy Technologies Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status